- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00025090
Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known if fluorouracil plus radiation therapy is more effective with or without additional chemotherapy in treating anal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus radiation therapy with or without additional chemotherapy in treating patients who have primary anal cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Compare the response rates in patients with primary epidermoid anal cancer treated with radiotherapy and fluorouracil with either mitomycin or cisplatin and with or without maintenance therapy.
- Compare local control and prevention or delay of disease dissemination in patients treated with these regimens.
OUTLINE: This is randomized, open-label, multicenter study. Patients are randomized to one of four treatment arms.
All patients undergo radiotherapy daily 5 days a week for 5.5 weeks. All patients also receive fluorouracil IV continuously over days 1-4 and 29-32.
- Arm I: Patients receive mitomycin IV on day 1.
- Arm II: Patients receive cisplatin IV on days 1 and 29.
- Arm III: Patients receive mitomycin as in arm I and maintenance therapy comprising fluorouracil IV continuously over days 1-4 and cisplatin IV on day 1 beginning 4-8 weeks after completion of primary therapy and repeating once 3 weeks later.
- Arm IV: Patients receive cisplatin as in arm II and maintenance therapy as in arm III.
Patients are followed at 2 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 600 patients (150 per treatment arm) will be accrued for this study.
Studietype
Registrering (Forventet)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Sheffield, Storbritannia, S1O 2SJ
- Cancer Research Centre at Weston Park Hospital
-
-
England
-
Harrow, England, Storbritannia, HA1 3UJ
- Northwick Park Hospital
-
Ipswich, England, Storbritannia, IP4 5PD
- Ipswich Hospital
-
Leeds, England, Storbritannia, LS16 6QB
- Cookridge Hospital
-
London, England, Storbritannia, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Storbritannia, NW1 2ND
- Cancer Research UK and University College London Cancer Trials Centre
-
Middlesbrough, England, Storbritannia, TS4 3BW
- James Cook University Hospital
-
Northwood, England, Storbritannia, HA6 2RN
- Mount Vernon Cancer Centre at Mount Vernon Hospital
-
Nottingham, England, Storbritannia, NG5 1PB
- Nottingham City Hospital
-
Sutton, England, Storbritannia, SM2 5PT
- Royal Marsden - Surrey
-
Westcliff-On-Sea, England, Storbritannia, SS0 0RY
- Southend University Hospital NHS Foundation Trust
-
-
Scotland
-
Aberdeen, Scotland, Storbritannia, AB25 2ZN
- Aberdeen Royal Infirmary
-
-
Wales
-
Cardiff, Wales, Storbritannia, CF14 2TL
- Velindre Cancer Center at Velindre Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed primary epidermoid anal cancer
- Squamous cell
- Basaloid
- Cloacogenic
- No adenocarcinoma, malignant melanoma, mucoepidermoid carcinoma, lymphoma, or microinvasive anal intraepithelial neoplasia (without evidence of invasive disease) in the anal canal or margin
- No metastatic disease
PATIENT CHARACTERISTICS:
Age:
- Not specified
Performance status:
- 0-2
Life expectancy:
- Not specified
Hematopoietic:
- WBC greater than 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin greater than 10 g/dL
Hepatic:
- Liver function tests no greater than 2 times normal
Renal:
- Glomerular filtration rate at least 50 mL/min
Cardiovascular:
- No cardiovascular disease
- No uncontrolled angina pectoris
- No heart failure
- No clinically significant cardiac arrhythmias
Other:
- HIV negative
- No other significant concurrent illness
- Not predominately bed-bound or frail
- No severe sepsis
- No other prior or concurrent cancer or illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy to pelvis
Surgery:
- Not specified
Other:
- No prior therapy for anal cancer
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Gjentaksfri overlevelse
|
Complete response rate at 6 months
|
Acute toxicity as measured up to 4 weeks after chemoradiation
|
Sekundære resultatmål
Resultatmål |
---|
Colostomy rate
|
In field recurrence rate as measured by confirmed disease within radiation therapy field
|
Cause-specific and overall survival
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Roger D. James, MD, Maidstone Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Tarmsykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolorektale neoplasmer
- Rektale neoplasmer
- Anus sykdommer
- Neoplasmer i anus
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Alkyleringsmidler
- Antibiotika, antineoplastisk
- Fluorouracil
- Mitomyciner
- Mitomycin
Andre studie-ID-numre
- CDR0000068911
- NCRI-ACT-II
- EU-20056
- UKCCCR-ACT-II
- ISRCTN26715889
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Analkreft
-
The Cleveland ClinicBard LtdFullført
-
Hospices Civils de LyonFullført
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtAnal plateepitelkarsinom | Stage III anal kreft AJCC v8 | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II anal kreft AJCC v8 | Stage IIA Anal Cancer AJCC v8 | Trinn 0 Anal Cancer AJCC v8Forente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtStage III anal kreft AJCC v8 | Analkanal plateepitelkarsinom | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II anal kreft AJCC v8 | Stage IIA Anal Cancer AJCC v8Forente stater
-
Tel-Aviv Sourasky Medical CenterRekrutteringIleal Pouch Anal AnastomosisIsrael
-
Sun Yat-sen UniversityPåmelding etter invitasjonAnal Canal Cancer | Anal plateepitelkarsinom | Analkreft | Anal Cancer Stadium I | Anal Cancer Stadium II | Anal Cancer Stadium IIIKina
-
Groupe Hospitalier Paris Saint JosephFullførtObstetrisk perineal skade og anal inkontinensFrankrike
-
Kasr El Aini HospitalFullførtEffekten av kaudal blokkering på intraoperativ anal sphincter muskeltonusEgypt
-
Assistance Publique Hopitaux De MarseilleFullførtAnal inkontinens eller forstoppelseFrankrike
-
Emory UniversityFullførtPerinatal og postpartum anal inkontinensForente stater
Kliniske studier på fluorouracil
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... og andre samarbeidspartnereUkjentNasofaryngealt karsinomKina
-
Sun Yat-sen UniversityUkjent
-
CStone PharmaceuticalsAktiv, ikke rekrutterendeIkke-opererbart lokalt avansert, tilbakevendende eller metastatisk esofageal plateepitelkarsinomKina
-
The Netherlands Cancer InstituteFullført
-
Actavis Inc.FullførtAktinisk keratoseForente stater
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalFullført
-
The Netherlands Cancer InstituteFullført
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundFullført
-
Boston UniversityRekrutteringOverfladisk basalcellekarsinom | Plateepitelkarsinom in situForente stater
-
Medical Research CouncilFullførtBlærekreft | Overgangscellekreft i nyrebekkenet og urinlederen | Kreft i urinrøretCanada, Storbritannia, Norge, New Zealand, Nederland, Sør-Afrika, Brasil, Finland